OncoImmunology (Jan 2019)

B cells in esophago-gastric adenocarcinoma are highly differentiated, organize in tertiary lymphoid structures and produce tumor-specific antibodies

  • Hans A. Schlößer,
  • Martin Thelen,
  • Axel Lechner,
  • Kerstin Wennhold,
  • Maria A. Garcia-Marquez,
  • Sacha I. Rothschild,
  • Elena Staib,
  • Thomas Zander,
  • Dirk Beutner,
  • Birgit Gathof,
  • Ramona Gilles,
  • Engin Cukuroglu,
  • Jonathan Göke,
  • Alexander Shimabukuro-Vornhagen,
  • Uta Drebber,
  • Alexander Quaas,
  • Christiane J. Bruns,
  • Arnulf H. Hölscher,
  • Michael S. Von Bergwelt-Baildon

DOI
https://doi.org/10.1080/2162402X.2018.1512458
Journal volume & issue
Vol. 8, no. 1

Abstract

Read online

Tumor-infiltrating lymphocytes (TILs) are correlated to prognosis of several kinds of cancer. Most studies focused on T cells, while the role of tumor-associated B cells (TABs) has only recently gained more attention. TABs contain subpopulations with distinct functions, potentially promoting or inhibiting immune responses. This study provides a detailed analysis of TABs in gastro-esophageal adenocarcinoma (EAC). Flow cytometric analyses of single cell suspensions of tumor samples, mucosa, lymph nodes and peripheral blood mononuclear cells (PBMC) of EAC patients and healthy controls revealed a distinct B cell compartment in cancer patients. B cells were increased in tumor samples and subset-analyses of TILs showed increased proportions of differentiated and activated B cells and an enrichment for follicular T helper cells. Confocal microscopy demonstrated that TABs were mainly organized in tertiary lymphoid structures (TLS), which resemble lymphoid follicles in secondary lymphoid organs. A panel of 34 tumor-associated antigens (TAAs) expressed in EAC was identified based on public databases and TCGA data to analyze tumor-specific B cell responses using a LUMINEXTM bead assay and flow cytometry. Structural analyses of TLS and the detection of tumor-specific antibodies against one or more TAAs in 48.1% of analyzed serum samples underline presence of anti-tumor B cell responses in EAC. Interestingly, B cells were decreased in tumors with expression of Programmed Death Ligand 1 or impaired HLA-I expression. These data demonstrate that anti-tumor B cell responses are an additional and underestimated aspect of EAC. Our results are of immediate translational relevance to emerging immunotherapies.

Keywords